for the Biotherapies in Uveitis (BioÚvea) Study Group* Purpose: To study the drug retention rate (DRR), causes, and predictors of discontinuation of adalimumab (ADA) in a real-world uveitis setting.Design: Multicentric, nationwide, registry-based, ambispective, observational study.Participants: Patients treated with ADA for noninfectious uveitis (NIU) in the Biotherapies for Uveitis (BioÚvea) Spanish registry from November 2016 to November 2017.Methods: Demographics, clinical data, timing, and reasons for discontinuation, if occurred, were recorded. The DRR and drug retention time (DRT) were estimated using the KaplaneMeier method. Median follow-up was analyzed by reverse KaplaneMeier. Log-rank test was used for comparisons. Cox proportional-hazards model (PHM) and propensity score matching were used to identify predictors for discontinuation due to inefficacy and adverse events.Main Outcome Measures: Drug retention rate and DRT. Results: A total of 392 patients were analyzed, including 218 women. Median age was 39 (interquartile range, 25) years. Nonanterior uveitis was recorded in 242 patients. Median follow-up was 49.07 (0.97e131.67) months, median DRT (survival) was 69.3 months, and 14 patients were lost to follow-up. The DRR at 6, 12, 24, and 60 months was 92.97%, 87.68%, 76.31%, and 54.28%, respectively. Adalimumab was discontinued in 151 patients. Discontinuation was due to lack or loss of efficacy in 74 patients, adverse event in 34 patients, and sustained quiescence in 25 patients. Recorded adverse events included infections in 10 patients and malignant neoplasms in 3 patients. Concurrent classic immunomodulatory therapy (IMT) was given to 251 patients. We did not find DRT differences regarding the use of concurrent IMT. Adalimumab was prescribed as a second or greater biotherapy line in 76 patients who showed shorter DRT (P ¼ 0.038). Starting ADA in nonbiotherapy-naive patients was a predictor for "discontinuation due to inefficacy," whereas undifferentiated uveitis was a predictor for "discontinuation due to adverse event." Drug retention time was significantly shorter when spared or intensified, mainly due to discontinuation after sustained quiescence.Conclusions: Drug retention rate of ADA in uveitis at 60 months was 54.28%, with a good safety profile. The use of concurrent IMT did not show a significant influence on DRT. The use of ADA as a second or further biotherapy could be predictive for discontinuation due to inefficacy. Undifferentiated uveitis may be prone to premature discontinuation of ADA due to adverse events. Ophthalmology 2020;127:814-825 ª 2019 by the American Academy of Ophthalmology Supplemental material available at www.aaojournal.org.Noninfectious uveitis (NIU) is composed of a large group of diseases that involve the inflammation of the intraocular tissues. 1 Approximately 20% of legal blindness has been attributed to NIU in developed countries. 2,3 The disease usually affects the working-age population, leading to a significant impact on patients' quality of life and welfare. 4,...

Although DCT is only affected by the mean thickness of zone II, GAT is influenced by CCT and the mean thickness of zones I, II, and III.

No abstract

No abstract

The specificity of TNT may be considered to be over 95% with a large number of examinations, and 90-100% with fewer examinations. At least five examinations are required for a basic interpretation of progression, and preferably more than six to guarantee the specificity of the result.